Name (Synonyms) | Correlation | |
---|---|---|
drug1077 | Human biological samples Wiki | 1.00 |
drug2176 | Saline Wiki | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.
Description: solicited local and systemic AEs after vaccination
Measure: Incidence of solicited adverse events Time: Through 1 year post vaccinationDescription: unsolicited AEs after vaccination
Measure: Incidence of unsolicited adverse events Time: Through 1 year post vaccinationDescription: percentage of subjects with SAEs
Measure: Incidence of serious adverse events Time: Through 1 year post vaccinationDescription: Change from baseline in antigen-specific binding antibody titers
Measure: Geometric mean titer (GMT) of antigen-specific binding antibody titers Time: Through 1 year post vaccinationDescription: Seroconversion rate can be calculated based on test results reaching the quantifiable antibody level after vaccination
Measure: Percentage of subjects who seroconverted after vaccination Time: Through 1 year post vaccinationDescription: NAb is regarded as produced when FRNT50 is detected more than four times the baseline after vaccination
Measure: Geometric mean titer (GMT) of neutralizing antibody level Time: Through 1 year post vaccinationDescription: Change from baseline in antigen-specific binding antibody titers
Measure: Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers Time: Through 1 year post vaccinationDescription: Antigen-specific IFN-γ T cell immune response assessed before/after vaccination
Measure: Change from baseline in antigen-specific IFN-g cellular immune response Time: Through 1 year post vaccination